seen from China
seen from United States
seen from United States
seen from Malaysia
seen from Malaysia
seen from United States
seen from Russia
seen from Türkiye
seen from United States
seen from China
seen from Armenia
seen from China
seen from Israel
seen from China
seen from China
seen from China
seen from Thailand
seen from Thailand
seen from China
seen from Thailand
A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice - Microbiology Research
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018). Article CAS PubMed PubMed Central Google Scholar Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117…
A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice - Microbiology Research
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018). Article CAS PubMed PubMed Central Google Scholar Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117…
CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8+ T cell exhaustion in colorectal cancer - New Study
CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8+ T cell exhaustion in colorectal cancer Summary CD160, a surface receptor on CD8+ T cells, plays a crucial role in resistance to anti-PD-1 immunotherapy in colorectal cancer (CRC). Research demonstrates that high CD160 expression on CD8+ T cells promotes T cell exhaustion, rendering them less effective at killing tumor cells…
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment - New Study
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment Summary Anti-PD-1 immunotherapy response in metastatic melanoma is linked to specific immune cell changes within the tumor. Responders exhibit an increased presence of circulating myeloid cells (like monocytes and dendritic cells) and T-cell…
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial - New Study
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary A correction was issued regarding the phase 2 SWOG S1512 trial, which investigated anti-PD-1 therapy (pembrolizumab) for unresectable desmoplastic melanoma. The correction addressed errors in the initial publication, primarily affecting data presentation and minor statistical…
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy - New Study
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy Summary Cancer-induced nerve damage can foster resistance to anti-PD-1 immunotherapy. Specifically, nerves damaged by the tumor release neuropeptides that suppress immune cell activity, particularly T cell function. This creates an immunosuppressive tumor microenvironment, hindering the effectiveness of anti-PD-1 drugs designed…
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial - New Study
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary The SWOG S1512 phase 2 trial investigated pembrolizumab (anti-PD-1 therapy) in patients with unresectable desmoplastic melanoma (DM), a rare and aggressive subtype. The study found pembrolizumab demonstrated a promising objective response rate (ORR) in DM patients. Importantly, the trial showed that a…
Profiling with senescence-associated secretory phenotype score identifies GDC-0879 as a small molecule sensitizing glioblastoma to anti-PD1 - New Study
Profiling with senescence-associated secretory phenotype score identifies GDC-0879 as a small molecule sensitizing glioblastoma to anti-PD1 Summary Glioblastoma (GBM) is a deadly brain cancer with limited treatment options, and immunotherapy’s effectiveness is often hindered. This research explores a new strategy by targeting cellular senescence, a state of irreversible cell cycle arrest, in…
